✦ LIBER ✦

616 Pimasertib (MSC1936369B/AS703026), a Selective Oral MEK1/2 Inhibitor, Shows Clinical Activity in Melanoma

✍ Scribed by Delord, J.P.; Houédé, N.; Awada, A.; Lebbe, C.; Lesimple, T.; Schellens, J.H.M.; Rottey, S.; Kefford, R.; Rejeb, N.; Raymond, E.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

600 Pharmacokinetics and Pharmacodynamic

✍ Houédé, N.; Delord, J.P.; Awada, A.; Lebbe, C.; Lesimple, T.; Schellens, J.H.M.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 58 KB

604 Safety and Recommended Phase II Dose

✍ Awada, A.; Delord, J.P.; Houédé, N.; Lebbe, C.; Lesimple, T.; Schellens, J.H.M.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 78 KB

608 Phase I Dose-escalation Trial of a S

✍ Naing, A.; Mita, M.; Komarnitsky, P.; Milner, A.; von Richter, O.; Ogden, J.; Pi 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 64 KB